Fibroadenoma and related tumours

Mansel, RE

doi:10.1016/b978-0-7020-2774-1.00011-6

Cited by 2 publications

(1 citation statement)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 Multiple studies have reported that the majority of fibroadenomas remain static or gradually increase in size until 1-3 cm in diameter after which they regress. 20,21 Based on these observations, it is recommended that fibroadenoma can be safely followed with USG, with surgery reserved for patients with large, symptomatic, or growing lesions. 5,6 In our study too, most fibroadenomas remained static in both the groups; although the follow-up was only for 6 months.…”

Section: Discussionmentioning

confidence: 99%

Double blind randomized controlled trial of efficacy of ormeloxifene for the treatment of fibroadenoma (The FIBROCENT study)

Agrawal,

Silodia,

Yadav

et al. 2024

World j. surg.

View full text Add to dashboard Cite

BackgroundWe evaluated the effectiveness of Ormeloxifene (Centchroman) on regression of Fibroadenoma in a double‐blind randomized controlled trial.MethodsPatients with biopsy proven Fibroadenoma were enrolled between March 2023 and October 2023 and divided in two arms‐ Ormeloxifene group and Placebo group. Effectiveness of the treatment was evaluated using USG. No residual mass was defined as complete regression and more than 30% decrease in size was considered as partial regression.ResultsA total of 130 consecutive patients with Fibroadenoma were randomized to Ormeloxifene group (n = 65) and Placebo Group (n = 65). Complete regression was observed in 9% (6/65) patients in Ormeloxifene group and 10.8% (7/65) in Placebo Group at the end of 12 weeks (p = 0.49). Twenty one patients taking Ormeloxifene reported adverse events as compared to none in the other group.ConclusionIn our study Ormeloxifene was not found to be effective in treatment of fibroadenoma and had concerning side effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Double blind randomized controlled trial of efficacy of ormeloxifene for the treatment of fibroadenoma (The FIBROCENT study)

Agrawal,

Silodia,

Yadav

et al. 2024

World j. surg.

View full text Add to dashboard Cite

show abstract

Spontaneous Infarction in a Fibroadenoma of the Breast

Toy¹,

Esen²,

Sönmez³

et al. 2011

Breast Care

View full text Add to dashboard Cite

Background: Fibroadenomas are common neoplasms in young women but occur in a wide age range from adolescent females to octogenians. Case Report: A 21-year-old female patient presented with a 10-week history of a mass in her breast. Ultrasound examination demonstrated a 3.5 × 3 cm, well-circumscribed, semisolid mass. An excisional biopsy but no fine needle aspiration was performed. The patient had no history of pregnancy or lactation, or trauma or infection to the area of the lesion. The histopathological examination showed a spontaneously infarcted fibroadenoma. Conclusions: Spontaneous infarction is an uncommon complication in fibroadenoma of the breast, and there are very few reported cases in the literature.

show abstract

Fibroadenoma and related tumours

Cited by 2 publications

References 65 publications

Double blind randomized controlled trial of efficacy of ormeloxifene for the treatment of fibroadenoma (The FIBROCENT study)

Double blind randomized controlled trial of efficacy of ormeloxifene for the treatment of fibroadenoma (The FIBROCENT study)

Spontaneous Infarction in a Fibroadenoma of the Breast

Contact Info

Product

Resources

About